ARCT

9.485

7.01% -0.715

Pre-mercato: 9.44 -0.045 -0.47%

Arcturus Therapeutics Holdings Inc (ARCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$10.20

Aprire:

$9.59

Volume 24 ore:

362.42K

Relative Volume:

0.90

Capitalizzazione di mercato:

$257.23M

Reddito:

$157.75M

Utile/perdita netta:

$-29.73M

Rapporto P/E:

-8.1767

EPS:

-1.16

Flusso di cassa netto:

$-21.00M

1 W Prestazione:

-20.96%

1M Prestazione:

-39.51%

6M Prestazione:

-61.69%

1 anno Prestazione:

-71.03%

Intervallo 1D:

$9.18

$9.80

Intervallo di 1 settimana:

$9.18

$12.10

Portata 52W:

$9.18

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Nome

Arcturus Therapeutics Holdings Inc

Settore

Healthcare (1163)

Industria

Biotechnology (678)

Telefono

(858) 900-2660

Indirizzo

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Dipendente

176

Cinguettio

@ArcturusRx

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

ARCT's Discussions on Twitter

Confronta ARCT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARCT Arcturus Therapeutics Holdings Inc	9.485	257.23M	157.75M	-29.73M	-21.00M	-1.16
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	66.76B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-28	Iniziato	BTIG Research	Buy
2024-08-12	Iniziato	Leerink Partners	Outperform
2023-12-13	Iniziato	Canaccord Genuity	Buy
2023-07-24	Iniziato	William Blair	Outperform
2023-05-11	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-11-14	Ripresa	Wells Fargo	Overweight
2022-11-10	Downgrade	Robert W. Baird	Neutral → Underperform
2022-11-03	Aggiornamento	Citigroup	Neutral → Buy
2022-11-02	Aggiornamento	Barclays	Underweight → Equal Weight
2022-08-10	Downgrade	Raymond James	Mkt Perform → Underperform
2022-07-19	Ripresa	Cantor Fitzgerald	Overweight
2022-05-11	Aggiornamento	Robert W. Baird	Underperform → Neutral
2022-04-21	Downgrade	Citigroup	Buy → Neutral
2022-01-31	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-08-12	Downgrade	Raymond James	Mkt Perform → Underperform
2021-08-11	Downgrade	Goldman	Neutral → Sell
2021-08-10	Downgrade	Robert W. Baird	Neutral → Underperform
2021-07-02	Iniziato	Cantor Fitzgerald	Overweight
2021-06-25	Ripresa	Goldman	Neutral
2021-06-21	Downgrade	Barclays	Equal Weight → Underweight
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-17	Downgrade	B. Riley Securities	Neutral → Sell
2021-01-19	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-15	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-07	Iniziato	Wells Fargo	Overweight
2020-12-29	Downgrade	Barclays	Overweight → Equal Weight
2020-12-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-29	Downgrade	Raymond James	Outperform → Mkt Perform
2020-12-29	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-23	Downgrade	ROTH Capital	Buy → Sell
2020-12-08	Reiterato	B. Riley Securities	Buy
2020-12-07	Reiterato	B. Riley Securities	Buy
2020-10-26	Iniziato	Barclays	Overweight
2020-10-06	Iniziato	Citigroup	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-30	Ripresa	ROTH Capital	Buy
2020-07-16	Iniziato	Raymond James	Outperform
2020-07-13	Iniziato	B. Riley FBR	Buy
2020-06-09	Downgrade	WBB Securities	Buy → Hold
2020-02-11	Iniziato	Robert W. Baird	Outperform
2020-02-07	Iniziato	Guggenheim	Buy
2020-02-06	Iniziato	Guggenheim	Buy
2019-04-05	Iniziato	H.C. Wainwright	Buy
2018-09-20	Aggiornamento	WBB Securities	Buy → Strong Buy
2018-01-22	Iniziato	Chardan Capital Markets	Buy

Mostra tutto

Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie

Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025

Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025

Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025

Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025

Mar 17, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - Markets Insider

Mar 12, 2025

Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025

Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025

Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025